ES2588778T3 - Moduladores de la interacción de astrina y raptor, y usos de los mismos en la terapia del cáncer - Google Patents
Moduladores de la interacción de astrina y raptor, y usos de los mismos en la terapia del cáncer Download PDFInfo
- Publication number
- ES2588778T3 ES2588778T3 ES13151022.4T ES13151022T ES2588778T3 ES 2588778 T3 ES2588778 T3 ES 2588778T3 ES 13151022 T ES13151022 T ES 13151022T ES 2588778 T3 ES2588778 T3 ES 2588778T3
- Authority
- ES
- Spain
- Prior art keywords
- astrin
- raptor
- mtorc1
- cells
- mtor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000618133 Homo sapiens Sperm-associated antigen 5 Proteins 0.000 title abstract description 59
- 102100021915 Sperm-associated antigen 5 Human genes 0.000 title abstract description 58
- 230000003993 interaction Effects 0.000 title abstract description 5
- 238000011275 oncology therapy Methods 0.000 title description 2
- 108010029031 Regulatory-Associated Protein of mTOR Proteins 0.000 abstract description 20
- 102100040969 Regulatory-associated protein of mTOR Human genes 0.000 abstract description 19
- 230000027455 binding Effects 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 39
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 39
- 206010028980 Neoplasm Diseases 0.000 description 19
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 19
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 19
- 230000006907 apoptotic process Effects 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 16
- 230000000694 effects Effects 0.000 description 11
- 230000035882 stress Effects 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000008187 granular material Substances 0.000 description 6
- 239000012133 immunoprecipitate Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
- 230000010335 redox stress Effects 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- 229960002930 sirolimus Drugs 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 101100087591 Mus musculus Rictor gene Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000037417 hyperactivation Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 102100032620 Cytotoxic granule associated RNA binding protein TIA1 Human genes 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 101150097381 Mtor gene Proteins 0.000 description 2
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 2
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000010384 proximity ligation assay Methods 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 101100039010 Caenorhabditis elegans dis-3 gene Proteins 0.000 description 1
- 101710086368 Cytotoxic granule associated RNA binding protein TIA1 Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102100022466 Eukaryotic translation initiation factor 4E-binding protein 1 Human genes 0.000 description 1
- 108050000946 Eukaryotic translation initiation factor 4E-binding protein 1 Proteins 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101000654853 Homo sapiens Cytotoxic granule associated RNA binding protein TIA1 Proteins 0.000 description 1
- 101000919019 Homo sapiens Probable ATP-dependent RNA helicase DDX6 Proteins 0.000 description 1
- 101000893689 Homo sapiens Ras GTPase-activating protein-binding protein 1 Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102100029480 Probable ATP-dependent RNA helicase DDX6 Human genes 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 description 1
- 108050004017 Ras GTPase-activating protein 1 Proteins 0.000 description 1
- 102100040854 Ras GTPase-activating protein-binding protein 1 Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 101150045355 akt1 gene Proteins 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- AQLMHYSWFMLWBS-UHFFFAOYSA-N arsenite(1-) Chemical compound O[As](O)[O-] AQLMHYSWFMLWBS-UHFFFAOYSA-N 0.000 description 1
- 230000009789 autophagic cell death Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 102000057748 human SPAG5 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000008600 mitotic progression Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 102000021127 protein binding proteins Human genes 0.000 description 1
- 108091011138 protein binding proteins Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000005531 stress granule assembly Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13151022.4A EP2755027B1 (en) | 2013-01-11 | 2013-01-11 | Modulators of the interaction of astrin and raptor, and uses thereof in cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2588778T3 true ES2588778T3 (es) | 2016-11-04 |
Family
ID=47563201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13151022.4T Active ES2588778T3 (es) | 2013-01-11 | 2013-01-11 | Moduladores de la interacción de astrina y raptor, y usos de los mismos en la terapia del cáncer |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10041933B2 (enExample) |
| EP (1) | EP2755027B1 (enExample) |
| JP (1) | JP6494112B2 (enExample) |
| ES (1) | ES2588778T3 (enExample) |
| WO (1) | WO2014108532A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11237168B2 (en) | 2019-06-26 | 2022-02-01 | St. Jude Children's Research Hospital | Method for identifying modulators of G3BP activity |
| CN110476877A (zh) * | 2019-08-15 | 2019-11-22 | 上海交通大学医学院附属瑞金医院 | 一种β细胞中特异性Raptor敲除同时GFP示踪的小鼠的制备方法 |
| CN113125747B (zh) * | 2021-03-15 | 2022-06-14 | 天津医科大学 | 一种isPLA-Seq的高通量检测蛋白质相互作用的方法和试剂盒及其应用 |
-
2013
- 2013-01-11 EP EP13151022.4A patent/EP2755027B1/en active Active
- 2013-01-11 ES ES13151022.4T patent/ES2588778T3/es active Active
-
2014
- 2014-01-13 US US14/758,461 patent/US10041933B2/en not_active Expired - Fee Related
- 2014-01-13 WO PCT/EP2014/050460 patent/WO2014108532A1/en not_active Ceased
- 2014-01-13 JP JP2015552068A patent/JP6494112B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US10041933B2 (en) | 2018-08-07 |
| EP2755027A1 (en) | 2014-07-16 |
| HK1199930A1 (en) | 2015-07-24 |
| WO2014108532A1 (en) | 2014-07-17 |
| JP2016511822A (ja) | 2016-04-21 |
| JP6494112B2 (ja) | 2019-04-03 |
| EP2755027B1 (en) | 2016-06-01 |
| US20150355166A1 (en) | 2015-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kaehler et al. | Ataxin-2-like is a regulator of stress granules and processing bodies | |
| Wei et al. | A new mechanism of RhoA ubiquitination and degradation: Roles of SCFFBXL19 E3 ligase and Erk2 | |
| Han et al. | Direct cellular delivery of human proteasomes to delay tau aggregation | |
| Ikeda et al. | YAP plays a crucial role in the development of cardiomyopathy in lysosomal storage diseases | |
| Wang et al. | The X-linked deubiquitinase USP9X is an integral component of centrosome | |
| US20130045214A1 (en) | P53 modulator and cancer target | |
| David-Watine | Silencing nuclear pore protein Tpr elicits a senescent-like phenotype in cancer cells | |
| Eid et al. | Genome-wide identification of CBX2 targets: insights in the human sex development network | |
| Quintero et al. | Transmembrane prostatic acid phosphatase (TMPAP) interacts with snapin and deficient mice develop prostate adenocarcinoma | |
| ES2588778T3 (es) | Moduladores de la interacción de astrina y raptor, y usos de los mismos en la terapia del cáncer | |
| Chowdhury et al. | Prohibitin confers cytoprotection against ISO-induced hypertrophy in H9c2 cells via attenuation of oxidative stress and modulation of Akt/Gsk-3β signaling | |
| Bullenkamp et al. | Apoptin interacts with and regulates the activity of protein kinase C beta in cancer cells | |
| Ying et al. | CCHCR1-astrin interaction promotes centriole duplication through recruitment of CEP72 | |
| Leem et al. | MDC1 is essential for G2/M transition and spindle assembly in mouse oocytes | |
| Liu et al. | PGC7 regulates maternal mRNA translation via AKT1-YBX1 interactions in mouse oocytes | |
| Cai et al. | The mitochondrial stress-induced protein carboxyl-terminal alanine and threonine tailing (msiCAT-tailing) promotes glioblastoma tumorigenesis by modulating mitochondrial functions | |
| Shanbhag et al. | An ATM-dependent transcriptional silencing program is transmitted through chromatin in cis to DNA double strand breaks | |
| Vit et al. | Cellular toxicity of iHAP1 and DT-061 does not occur through PP2A-B56 targeting | |
| Strauss et al. | MDC1 is ubiquitylated on its tandem BRCT domain and directly binds RAP80 in a UBC13-dependent manner | |
| Koloko Ngassie et al. | Hyperoxia-induced senescence in fetal airway smooth muscle cells: Role of mitochondrial reactive oxygen species and endoplasmic reticulum stress | |
| Wang et al. | PAK4 promotes the cytoskeletal organization and meiotic maturation via phosphorylating DDX17 in oocyte | |
| Chen et al. | Ubiquitin phosphorylation accelerates protein aggregation and promotes neurodegeneration in the aging brain | |
| Bowen et al. | Mitochondrial defects and metabolic vulnerabilities in Lynch syndrome-associated MSH2-deficient endometrial cancer | |
| Roy et al. | A phospho-regulated signal motif determines subcellular localization of α-TAT1 for dynamic microtubule acetylation | |
| Wu et al. | LUBAC assembles a signaling platform at mitochondria for signal amplification and shuttling of NF-ĸB to the nucleus |